| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1Oncodevelopmental Biology Program, The Burnham Institute, La Jolla, California; 2The Institute for Molecular Biology and Biotechnology, McMaster University, Hamilton, Ontario, Canada; 3Molecular Oncology Group, Departments of Medicine and Biochemistry, McGill University, Montreal, Quebec, Canada; and 4Pathology Department, University of California, Davis, California
The Neu (ErbB2, HER2) member of the epidermal growth factor receptor family is implicated in many human breast cancers. We have tested the importance of increased angiogenic signaling in the NeuYD [mouse mammary tumor virus (MMTV)-Neundl-YD5] mammary tumor model. Transgenic mice expressing vascular endothelial growth factor (VEGF)164 from the MMTV promoter were generated. These mice expressed VEGF164 RNA and protein at 20- to 40-fold higher levels throughout mammary gland development but exhibited normal mammary gland development and function. However, in combination with the NeuYD oncogene, VEGF164 expression resulted in increased vascularization of hyperplastic mammary epithelium and dramatic acceleration of tumor appearance from 111 to 51 days. Gene expression profiling also indicated that the VEGF-accelerated tumors were substantially more vascularized and less hypoxic. The preferential vascularization of early hyperplastic portions of mammary epithelia in NeuYD;MMTV-VEGF animals was associated with NeuYD RNA expression, disorganization of the tight junctions, and overlapping transgenic VEGF expression. NeuYD;MMTV-VEGF164 bigenic, tumor-bearing animals resulted in an average of 10 tumor cell colonies/lung lodged within vascular spaces. No similar lung colonies were found in control NeuYD mice with similar tumor burdens. Overall, these results demonstrate the angiogenic restriction of early hyperplastic mammary lesions. They also reinforce in vivo the importance of activated Neu in causing disorganization of mammary luminal epithelial cell junctions and provide support for an invasion-independent mechanism of metastasis.
This article has been cited by other articles:
![]() |
M. S. Denzel, L. W. Hebbard, G. Shostak, L. Shapiro, R. D. Cardiff, and B. Ranscht Adiponectin Deficiency Limits Tumor Vascularization in the MMTV-PyV-mT Mouse Model of Mammary Cancer Clin. Cancer Res., May 15, 2009; 15(10): 3256 - 3264. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Fereshteh, M. T. Tilli, S. E. Kim, J. Xu, B. W. O'Malley, A. Wellstein, P. A. Furth, and A. T. Riegel The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for Neu (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice Cancer Res., May 15, 2008; 68(10): 3697 - 3706. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Hebbard, M. Garlatti, L. J.T. Young, R. D. Cardiff, R. G. Oshima, and B. Ranscht T-cadherin Supports Angiogenesis and Adiponectin Association with the Vasculature in a Mouse Mammary Tumor Model Cancer Res., March 1, 2008; 68(5): 1407 - 1416. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-S. Huang, J.-W. Liao, and M.-L. Hu Lycopene Inhibits Experimental Metastasis of Human Hepatoma SK-Hep-1 Cells in Athymic Nude Mice J. Nutr., March 1, 2008; 138(3): 538 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Allen, J. T. Garrett, S. V. Rawale, A. L. Jones, G. Phillips, G. Forni, J. C. Morris, R. G. Oshima, and P. T. P. Kaumaya Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo J. Immunol., July 1, 2007; 179(1): 472 - 482. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ma, S. L. Gibson, M. A. Byrne, J. Zhang, M. F. White, and L. M. Shaw Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis Mol. Cell. Biol., December 15, 2006; 26(24): 9338 - 9351. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Riou, R. Saffroy, C. Chenailler, B. Franc, C. Gentile, E. Rubinstein, T. Resink, B. Debuire, D. Piatier-Tonneau, and A. Lemoine Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma FASEB J, November 1, 2006; 20(13): 2291 - 2301. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhang, L. C. Stephens, and R. Kumar Metastasis Tumor Antigen Family Proteins during Breast Cancer Progression and Metastasis in a Reliable Mouse Model for Human Breast Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1479 - 1486. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cecena, F. Wen, R. D. Cardiff, and R. G. Oshima Differential Sensitivity of Mouse Epithelial Tissues to the Polyomavirus Middle T Oncogene Am. J. Pathol., January 1, 2006; 168(1): 310 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liu, A. Howes, J. Lesperance, W. B. Stallcup, C. A. Hauser, K. Kadoya, R. G. Oshima, and R. T. Abraham Antitumor Activity of Rapamycin in a Transgenic Mouse Model of ErbB2-Dependent Human Breast Cancer Cancer Res., June 15, 2005; 65(12): 5325 - 5336. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |